Central Sensitization in Painful and Painless Diabetic Peripheral Neuropathy

NCT ID: NCT07316322

Last Updated: 2026-01-05

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 128 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-12-15
• Study Completion Date: 2026-09-15

Brief Summary

This research is structured as a cross-sectional observational study. The primary objective is to compare central sensitization across painful and painless phenotypes of diabetic peripheral neuropathy. The study will be conducted among individuals diagnosed with type 2 diabetes mellitus at the Department of Geriatrics, İnönü University Turgut Özal Medical Center. All assessments will be administered in accordance with a rigorously standardized protocol.

Eligible participants will include individuals aged 18 to 80 years who have had a confirmed diagnosis of type 2 diabetes mellitus for at least one year, are capable of comprehending and following verbal instructions in Turkish required for the study procedures, and provide written informed consent.

All statistical analyses will be performed using IBM SPSS Statistics (v.29, Armonk, NY, USA) and JASP (v.0.18, Amsterdam, Netherlands).

Detailed Description

Diabetes mellitus (DM) is a well-known metabolic disease characterized by organ dysfunction that arises directly or indirectly from the effects of chronic hyperglycemia, affecting a substantial portion of the global population. According to the International Diabetes Federation, the global prevalence of diabetes was estimated at 9.3% in 2019, with 463 million individuals living with the disease, and this prevalence is projected to rise to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045. Both Type 2 Diabetes (T2DM) and Type 1 Diabetes (T1DM) lead to elevated glucose concentrations and increased inflammatory processes, resulting in a wide range of complications including diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, cardiovascular diseases, musculoskeletal disorders, impaired fracture and wound healing, and pain. Diabetic polyneuropathy (DPN) is a clinical syndrome characterized by pain associated with lesions of the somatosensory nervous system. Between 10-20% of individuals with diabetes experience pain due to the presence of peripheral neuropathy, and there is no universally accepted gold standard for diagnosing DPN; accurately identifying painful DPN remains challenging, particularly because neuropathic pain is often difficult to distinguish from non-neuropathic pain. The mechanisms of neuropathic pain are complex. Peripheral tissue damage can trigger peripheral sensitization; however, central sensitization of the central nervous system plays the predominant role. DM may affect central nervous system processes, leading to central sensitization and dysfunction of pain modulation. Central sensitization is defined as an increased responsiveness of the central nociceptive system, which contributes to the amplification and spread of pain. Recent studies over the past five years have demonstrated that central neuropathic mechanisms may contribute to diabetes-related pain, similar to other neuropathic pain conditions. While there is extensive literature evaluating diabetic neuropathic pain, studies specifically investigating nociceptive pain remain limited. The primary aim of this study is to compare central sensitization across painful and painless diabetic peripheral neuropathy phenotypes.This research is planned as a cross-sectional observational study. It will be conducted in individuals diagnosed with Type 2 diabetes at the Department of Geriatrics, Turgut Özal Medical Center, İnönü University. All assessments will be performed according to a predetermined standardized protocol. Individuals aged 18-80 years who have had a diagnosis of Type 2 diabetes mellitus for at least one year and who can understand and follow verbal instructions in Turkish will be included. Initially, data regarding age, height, weight, smoking and alcohol use, duration of diagnosis, comorbidities, current medications and duration of use, biochemical test results, surgical history, and educational and income levels will be collected. Body mass index will be calculated for all participants. All statistical analyses will be conducted using IBM SPSS Statistics (v.29, Armonk, NY, USA) and JASP (v.0.18, Amsterdam, Netherlands). Descriptive data will be presented as mean ± SD for continuous variables and as percentages/frequencies for categorical variables. Data distribution will be assessed using the Shapiro-Wilk test. Between-group comparisons for continuous variables will be performed using one-way ANOVA or the Kruskal-Wallis test depending on distribution; when significant differences are identified, Tukey HSD or Dunn-Bonferroni post-hoc analyses will be conducted. Categorical variables will be analyzed using chi-square or Fisher's exact tests. Between-group differences will be further examined using one-way ANCOVA, with age, sex, HbA1c, diabetes duration, BMI, MNSI-clinical score, and DN4 score included as covariates. Effect sizes will be reported as partial eta-squared (η²ₚ) for interaction effects and Cohen's d for pairwise comparisons. Correlation analyses will be performed using Pearson or Spearman methods. Effect size assumptions were based on findings from a previous study investigating CPM effectiveness in individuals with diabetic polyneuropathy. That study reported mean CPM values of approximately -7.4 ± 1.0 in the painful DPN group and -2.3 ± 1.6 in the painless DPN group, yielding a mean difference of 5.1 and a pooled SD of 1.35, corresponding to Cohen's d ≈ 0.6. When adapted to a three-group phenotypic design, this effect size was converted to f ≈ 0.30 using the formula f = d / 2. Using these parameters (f = 0.30, α = 0.05, power = 0.80, number of groups = 3), a priori power analysis yielded a required sample size of 111 participants. Accounting for potential data loss, the sample size was increased by 15%, resulting in a final target of 128 participants (approximately 42-43 per group).

Conditions

Diabetes Mellitus (DM)

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Painful DPN Group

The study will include individuals aged 18-80 years who have been diagnosed with diabetic neuropathy, show a positive result on the MNSI-clinical assessment, and have a DN4 score of ≥4.This study is entirely observational and cross-sectional in nature, and no therapeutic intervention will be administered to the participants.

No interventions assigned to this group

Painless DPN Group

The study will include individuals aged 18-80 years who have been diagnosed with diabetes mellitus, have a positive MNSI-clinical assessment, and a DN4 score of \<4. This study is entirely observational and cross-sectional in nature, and no therapeutic intervention will be administered to the participants.

No interventions assigned to this group

Diabetic Control Group Without Diabetic Peripheral Neuropathy (DPN)

The study will include individuals aged 18-80 years who have been diagnosed with diabetes mellitus, have a negative MNSI-clinical assessment, and a DN4 score of \<4. This study is entirely observational and cross-sectional in nature, and no therapeutic intervention will be administered to the participants.

No interventions assigned to this group

Healthy Control Group

The study will include individuals aged 18-80 years who do not have a diagnosis of diabetes mellitus, have a negative MNSI-clinical assessment, and a DN4 score of \<4. This study is entirely observational and cross-sectional in nature, and no therapeutic intervention will be administered to the participants.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Being between 18 and 80 years of age
• Having a diagnosis of Type 2 diabetes mellitus for at least 1 year
• Providing written informed consent to participate in the study

Exclusion Criteria

• Non-diabetic causes of polyneuropathy (alcohol, chemotherapy, vitamin deficiencies, renal failure, hypothyroidism, etc.)
• Active ulcer, infection, or severe vascular insufficiency in the lower extremity
• Central nervous system disorders (stroke, multiple sclerosis, spinal cord injury, etc.)
• Skin lesions, dermatitis, wounds, or infection in the test areas (foot or forearm)
• Peripheral entrapment neuropathies or related radiculopathies (e.g., carpal tunnel syndrome, C7-C8 radiculopathy)
• Chronic widespread pain syndrome (fibromyalgia, etc.) or active flaring rheumatologic disease
• Dose change within the last 2-4 weeks in medications affecting pain modulation (gabapentinoids, SNRI/TCA, opioids, hypnotics, etc.)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Inonu University

OTHER

Sponsor Role: lead

Responsible Party

Zeynal Yasacı

Doctor Lecturer

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Zeynal Yasacı

Role: PRINCIPAL_INVESTIGATOR

Inonu University

Locations

Inonu University Turgut Ozal Medical Center, Malatya

Malatya, , Turkey (Türkiye)

Countries

Turkey (Türkiye)

Central Contacts

Gamze Levent

Role: CONTACT

uzunhasanoglugamze@gmail.com

+905455169598

Zeynal Yasacı

Role: CONTACT

zeynal.yasaci@inonu.edu.tr

+905075409791

Facility Contacts

Inonu University Turgut Ozal Medical Center

Role: primary

totm@inonu.edu.tr

+904223410660

Funda Datlı Yakaryılmaz

Role: backup

+905057805503

References

Granovsky Y, Shafran Topaz L, Laycock H, Zubiedat R, Crystal S, Buxbaum C, Bosak N, Hadad R, Domany E, Khamaisi M, Sprecher E, Bennett DL, Rice A, Yarnitsky D. Conditioned pain modulation is more efficient in patients with painful diabetic polyneuropathy than those with nonpainful diabetic polyneuropathy. Pain. 2022 May 1;163(5):827-833. doi: 10.1097/j.pain.0000000000002434.

Reference Type: BACKGROUND

PMID: 34371518 (View on PubMed)

İrem Mıhçıoğlu CM, Hacer Hicran Mutlu. Uykusuzluk Şikayetleri ve Uyku Kalitesi Temel Ölçeğinin Türkçe Geçerlilik ve Güvenirliği. 2017.

Reference Type: BACKGROUND

Rabia Hacıhasanoğlu PK, Arzu Yıldırım,Seval Uslu, . Bir Sağlık Ocağına Başvuran Kronik Hastalığı Olan Bireylerde Anksiyete ve Depresyon 2010.

Reference Type: BACKGROUND

Öznur Tunca Yılmaz YY, Fatma Uygur, Naime Uluğ Tampa Kinezyofobi Ölçeği'nin Türkçe versiyonu ve test-tekrar test güvenirliği 2011.

Reference Type: BACKGROUND

Damla Karabay FT, Merve Keskin, Orhan Öztürk,Merve Kurt,Derya Özer Kaya. Ruminasyonun Tanınması ve Ağrı Deneyimi ve Fiziksel Aktivite ile İlişkisinin İncelenmesi: Geleneksel Derleme. 2023.

Reference Type: BACKGROUND

Robinson CL, Phung A, Dominguez M, Remotti E, Ricciardelli R, Momah DU, Wahab S, Kim RS, Norman M, Zhang E, Hasoon J, Orhurh V, Viswanath O, Yazdi C, Chen GH, Simopoulos TT, Gill J. Pain Scales: What Are They and What Do They Mean. Curr Pain Headache Rep. 2024 Jan;28(1):11-25. doi: 10.1007/s11916-023-01195-2. Epub 2023 Dec 7.

Reference Type: BACKGROUND

PMID: 38060102 (View on PubMed)

Aktar Reyhanioglu D, Adiyaman SC, Bektas M, Bulut O, Ozgen Saydam B, Bayraktar F, Kara B. Validity and reliability of the Turkish version of the Michigan Neuropathy Screening Instrument. Turk J Med Sci. 2020 Jun 23;50(4):789-797. doi: 10.3906/sag-1906-63.

Reference Type: BACKGROUND

PMID: 32178509 (View on PubMed)

Unal-Cevik I, Sarioglu-Ay S, Evcik D. A comparison of the DN4 and LANSS questionnaires in the assessment of neuropathic pain: validity and reliability of the Turkish version of DN4. J Pain. 2010 Nov;11(11):1129-35. doi: 10.1016/j.jpain.2010.02.003. Epub 2010 Apr 24.

Reference Type: BACKGROUND

PMID: 20418179 (View on PubMed)

Düzce E. Santral Sensitizasyon Ölçeğinin Türkçe Geçerlilik ve Güvenilirliği. 2017.

Reference Type: BACKGROUND

Neblett R, Cohen H, Choi Y, Hartzell MM, Williams M, Mayer TG, Gatchel RJ. The Central Sensitization Inventory (CSI): establishing clinically significant values for identifying central sensitivity syndromes in an outpatient chronic pain sample. J Pain. 2013 May;14(5):438-45. doi: 10.1016/j.jpain.2012.11.012. Epub 2013 Mar 13.

Reference Type: BACKGROUND

PMID: 23490634 (View on PubMed)

Fischer TZ, Waxman SG. Neuropathic pain in diabetes--evidence for a central mechanism. Nat Rev Neurol. 2010 Aug;6(8):462-6. doi: 10.1038/nrneurol.2010.90. Epub 2010 Jul 13.

Reference Type: BACKGROUND

PMID: 20625378 (View on PubMed)

Ma YC, Kang ZB, Shi YQ, Ji WY, Zhou WM, Nan W. The Complexity of Neuropathic Pain and Central Sensitization: Exploring Mechanisms and Therapeutic Prospects. J Integr Neurosci. 2024 Apr 25;23(5):89. doi: 10.31083/j.jin2305089.

Reference Type: BACKGROUND

PMID: 38812380 (View on PubMed)

Celik S, Yenidunya G, Temel E, Purisa S, Uzum AK, Gul N, Cinkil G, Dinccag N, Satman I. Utility of DN4 questionnaire in assessment of neuropathic pain and its clinical correlations in Turkish patients with diabetes mellitus. Prim Care Diabetes. 2016 Aug;10(4):259-64. doi: 10.1016/j.pcd.2015.11.005. Epub 2015 Dec 31.

Reference Type: BACKGROUND

PMID: 26749091 (View on PubMed)

Eitner A. [Diabetes mellitus-a risk factor for pain]. Schmerz. 2025 Oct;39(5):350-358. doi: 10.1007/s00482-025-00900-x. Epub 2025 Aug 28. German.

Reference Type: BACKGROUND

PMID: 40875021 (View on PubMed)

Lu Y, Wang W, Liu J, Xie M, Liu Q, Li S. Vascular complications of diabetes: A narrative review. Medicine (Baltimore). 2023 Oct 6;102(40):e35285. doi: 10.1097/MD.0000000000035285.

Reference Type: BACKGROUND

PMID: 37800828 (View on PubMed)

Other Identifiers

1003

Identifier Type: -

Identifier Source: org_study_id